KRAS and non-small cell lung carcinoma: Our results showed that each of the WEE1 inhibitors, adavosertib and ZN-c3, inhibited cell viability in a dose-dependent manner in all KRAS-mutated NSCLC cell lines with TP53 mutations tested.